Drug Price Trends for daliresp

Average Pharmacy Cost for daliresp

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DALIRESP 250 MCG TABLET	00310-0088-28	14.10775	EACH	2024-12-18
DALIRESP 250 MCG TABLET	00310-0088-39	14.10775	EACH	2024-12-18
DALIRESP 500 MCG TABLET	00310-0095-30	14.17327	EACH	2024-12-18
DALIRESP 500 MCG TABLET	00310-0095-90	14.17327	EACH	2024-12-18
DALIRESP 250 MCG TABLET	00310-0088-39	14.09273	EACH	2024-11-20
DALIRESP 500 MCG TABLET	00310-0095-30	14.17258	EACH	2024-11-20

Daliresp Market Analysis and Financial Projection

Market Analysis and Price Projections for DALIRESP

Introduction

DALIRESP (roflumilast) is a prescription medication used to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations. Here, we will delve into the market analysis and price projections for this drug.

Market Demand and Patient Population

DALIRESP is indicated for a specific subset of COPD patients, namely those with severe COPD and a history of exacerbations. The demand for this medication is driven by the prevalence of COPD, which is a significant health issue globally. The patient population for DALIRESP includes adults with severe COPD, particularly those who have experienced frequent exacerbations, making it a critical treatment option for managing this chronic condition[1].

Pricing and Cost Analysis

The pricing of DALIRESP varies based on the dosage, quantity, and the pharmacy from which it is purchased.

Retail Prices

• For a supply of 30 tablets of 500 mcg DALIRESP, the retail price can range from approximately $559.44 to $563.71, depending on the pharmacy[5][2].
• Here is a breakdown of prices at different pharmacies:
  • CVS Pharmacy: $429.90
  • Walmart: $310.56
  • Walgreens: $451.97
  • Kroger Pharmacy: $449.23
  • Albertsons Pharmacy: $376.97
  • Rite Aid Pharmacy: $450.90[5].

Discounted Prices

Using prescription discount cards, such as those offered by SingleCare, patients can significantly reduce the cost of DALIRESP. For example, with a SingleCare discount card, the price for 30 tablets of 500 mcg DALIRESP can be as low as $22.86 at certain pharmacies[5].

Generic Version

The FDA has approved a generic version of DALIRESP, which is roflumilast. However, the pricing information for the generic version is not widely available, suggesting it may not be commercially available yet or may vary significantly by region[2][5].

Market Competition

The market for COPD treatments is competitive, with various medications available, including bronchodilators and other phosphodiesterase-4 inhibitors. However, DALIRESP holds a unique position due to its specific indication for reducing COPD exacerbations in patients with severe disease.

New Entrants

Recent approvals of new COPD treatments, such as ensifentrine by Verona Pharma, may impact the market dynamics. Ensifentrine, with its dual mechanism of action, is priced at a wholesale price of $2,950 per month, which is significantly higher than DALIRESP. However, the cost-effectiveness of these new drugs is still under evaluation, and their impact on the market share of DALIRESP will depend on clinical outcomes and patient benefit[3].

Price Projections

Current Trends

Given the current pricing and the availability of discount programs, the cost of DALIRESP is expected to remain relatively stable for cash-paying customers. However, prices can fluctuate based on pharmacy stock, location, and the use of discount cards.

Future Outlook

• Generic Competition: Once the generic version of roflumilast becomes widely available, it is likely to reduce the market share and pricing of the brand-name DALIRESP.
• New Treatments: The entry of new drugs like ensifentrine could lead to a shift in treatment preferences, potentially affecting the demand for DALIRESP. However, the high price point of these new treatments may limit their adoption, at least in the short term.
• Healthcare Policies: Changes in healthcare policies, reimbursement rates, and insurance coverage can also influence the pricing and market demand for DALIRESP.

Adverse Reactions and Patient Compliance

The side effect profile of DALIRESP, which includes common adverse reactions such as diarrhea, nausea, and weight loss, can impact patient compliance and, by extension, market demand. Regular monitoring of weight and other adverse reactions is recommended, which may affect the long-term use of the drug[1].

Conclusion

DALIRESP remains a significant treatment option for patients with severe COPD, despite the competitive landscape and potential future challenges from generic versions and new treatments. The pricing of DALIRESP is influenced by various factors, including pharmacy prices, discount programs, and the availability of generic alternatives.

Key Takeaways

• Market Demand: Driven by the prevalence of severe COPD and the need for exacerbation reduction.
• Pricing: Varies by pharmacy and can be significantly reduced with discount cards.
• Generic Version: Approved but not yet widely available commercially.
• Market Competition: New treatments like ensifentrine may impact market dynamics.
• Price Projections: Stable for now, but potentially influenced by generic competition and new treatments.

FAQs

Q: What is the primary indication for DALIRESP?

A: DALIRESP is indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

Q: How much does DALIRESP typically cost?

A: The retail price for 30 tablets of 500 mcg DALIRESP can range from approximately $310 to $563, depending on the pharmacy. However, with discount cards, the price can be significantly lower.

Q: Is there a generic version of DALIRESP available?

A: Yes, the FDA has approved a generic version of DALIRESP (roflumilast), but it is not yet widely available commercially.

Q: What are the common adverse reactions associated with DALIRESP?

A: Common adverse reactions include diarrhea, nausea, weight loss, headache, and back pain. Serious adverse reactions can include psychiatric events and rare instances of suicidal ideation.

Q: How does the pricing of DALIRESP compare to new COPD treatments?

A: New treatments like ensifentrine are priced significantly higher than DALIRESP, with a wholesale price of $2,950 per month for ensifentrine compared to the retail price range of DALIRESP.

Sources

1. DALIRESP® (roflumilast) tablets - accessdata.fda.gov
2. Daliresp Prices, Coupons, Copay Cards & Patient Assistance - drugs.com
3. Verona Pharma Drug With Dual Mechanism Lands FDA Approval in ... - medcitynews.com
4. AstraZeneca 8 February 2024 FY and Q4 2023 results - astrazeneca.com
5. Daliresp Coupons & Prices - singlecare.com